[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444075":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":44,"collaborators":46,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AYA cancer patients",null,"Patients aged 18-39 years, with a first histological and\u002For cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.",[13],"Procedure: Blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Blood sampling","Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).",[9],[21],{"name":22,"affiliation":5,"role":23},"J. Nuver, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+31 50 361 2821","j.nuver@umcg.nl",[30],{"facility":5,"status":31,"city":32,"state":10,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Groningen","9713 GZ","Netherlands",{"type":36,"coordinates":37},"Point",[38,39],6.56667,53.21917,{"lat":39,"lon":38},[42,43],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[47],{"name":48,"class":49},"UMCG Kanker Researchfonds","UNKNOWN","100444075",false,"NCT05062707","Early Ageing During Therapy in AYA Cancer Patients","Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients","Inclusion Criteria:\n\n* Aged 18-39 years at cancer diagnosis\n* Having a histologically and\u002For cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.\n* Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.\n\nExclusion Criteria:\n\n* patients who are not able to understand the patient information letter and informed consent form\n* patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis\n* patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).","ALL","18 Years","39 Years",{"count":60,"type":61},120,"ESTIMATED","OBSERVATIONAL","Longitudinal cohort study; measurements before start of systemic therapy and one year later.",[65,66,67,68,69,70,71,72],"Cancer","Leukemia","Hodgkin Lymphoma","Testicular Cancer","Osteosarcoma","Ewing Sarcoma","Breast Cancer","Cervical Cancer","2025-05-12",{"date":75,"type":76},"2025-05-13","ACTUAL",{"date":78,"type":76},"2022-02-10",{"date":80,"type":61},"2025-07",{"name":5,"class":6},1]